Abstract
Objectives To estimate the short-term effect of stringent lockdown policies on non-COVID-19 mortality and explore the heterogeneous impacts of lockdowns in China after the COVID-19 outbreak.
Design Employing a difference-in-differences method.
Setting Using comprehensive death records covering around 300 million Chinese people, we estimate the impacts of city and community lockdowns on non-COVID-19 mortality outside of Wuhan.
Participants 44,548 deaths recorded in 602 counties or districts by the Disease Surveillance Point System of the Chinese Center for Disease Control and Prevention from 1 January 2020 to14 March 2020.
Results We find that lockdowns reduced the number of non-COVID-19 deaths by 4.9% (cardiovascular deaths by 6.2%, injuries by 9.2%, and non-COVID-19 pneumonia deaths by 14.3%). A back-of-the-envelope calculation shows that more than 32,000 lives could have been saved from non-COVID-19 diseases/causes during the 40 days of the lockdown on which we focus.
Main outcome measures Weekly numbers of deaths from all causes without COVID-19, cardiovascular diseases, injuries, pneumonia, neoplasms, chronic respiratory diseases, and other causes were used to estimate the associations between lockdown policies and mortality.
Conclusions The results suggest that the rapid and strict virus countermeasures not only effectively controlled the spread of COVID-19 but also brought about unintended short-term public health benefits. The health benefits are likely driven by significant reductions in air pollution, traffic, and human interactions during the lockdown period. These findings can help better inform policymakers around the world about the benefits and costs of lockdowns policies in dealing with the COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The project is funded by the National Key R&D Program of China (2018YFC1315301), Peking University Research Grant (7100602966), Anti-epidemic Fund 2.0 from HK government, and HKUST School-Based Initiative (SBI17HS02).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All relevant ethical guidelines have been followed. There is not IRB/oversight body that directly relevant to this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The DSPs data are proprietary data owned by the Chinese CDC. They can be accessed through application to the National Center for Chronic and Noncommunicable Disease Control and Prevention (a subsidiary of the Chinese CDC). The codes necessary to re-produce all the tables in the paper are ready to submit to the journal as supplementary materials or to post on a public repository.
